←Search results

Search “OpenAI”

By relevance · Total 3757 results Clear search

Wednesday

  1. FactRelated story

    OpenAI says GPT-Rosalind proposes new leads for neurodegenerative disease drug discovery

    On October 21, 2026, OpenAI said that GPT-Rosalind proposed new leads in drug discovery: after the DCTN1 gene associated with Perry syndrome was disrupted, the expression of genes related to cholesterol synthesis increased in mouse brain data, and the model inferred from this that cholesterol may not reach the locations neurons require. OpenAI said that, in collaboration with Perturb Bio and Scripps Research, thousands of GPT-Rosalind agents worked in parallel to link gene expression results from millions of mouse brain cells with scientific literature within 32 minutes, and said it is expanding this collaboration to find new drug targets. Other reports said that the work aggregated the reports of individual agents into a public reasoning graph, and that a companion preprint was released on bioRxiv on October 16, 2026, and has not yet undergone peer review.

    Matched fieldsTitle

    View story:OpenAI says GPT-Rosalind offers new leads for neurodegenerative disease drug discovery

  2. Story7 reports · 2 facts

    OpenAI acquires biotech AI startup Orchestra Bio

    On October 21, 2026, OpenAI announced the acquisition of biotech AI startup Orchestra Bio. According to OpenAI, the platform helps biopharma teams coordinate complex drug development processes, and OpenAI said it will continue building on its life science research models and tools Rosalind to streamline these operational processes and bring new therapies to patients faster. On the same day, OpenAI co-founder Greg Brockman commented on the acquisition, saying that accelerating drug development is an extremely exciting and promising emerging application direction for OpenAI models. The transaction amount has not been disclosed, and there is no further factual disclosure on the specific integration arrangements and business progress after the acquisition.

    On October 21, 2026, OpenAI announced the acquisition of biotech AI startup Orchestra Bio. According to OpenAI, the platform helps biopharma teams coordinate complex drug development processes, and OpenAI said it will continue building on its life science research models and tools Rosalind to streamline these operational processes and bring new therapies to patients faster. On the same day, OpenAI co-founder Greg Brockman commented on the acquisition, saying that accelerating drug development is

    Matched fieldsTitle

  4. Story3 reports · 1 facts

    OpenAI accelerates push for about $30 billion in financing

    OpenAI is accelerating its push for about $30 billion in financing. According to Reuters, OpenAI is aiming to complete this funding round at a valuation of more than $1.4 trillion before Anthropic goes public, a valuation at least 64% higher than the $852 billion it reached in March. OpenAI hopes to lock in commitments before Anthropic files its S-1 and lists in mid-November, so as to avoid a direct comparison. Subsequent reports said existing investors such as SoftBank and Abu Dhabi's MGX are in talks to participate; OpenAI told investors that growth accelerated after the release of GPT-6 Astra, with annualized revenue already reaching $50 billion and expected to rise to $70 billion by the end of the year. The financing is still in progress.

    OpenAI is accelerating its push for about $30 billion in financing. According to Reuters, OpenAI is aiming to complete this funding round at a valuation of more than $1.4 trillion before Anthropic goes public, a valuation at least 64% higher than the $852 billion it reached in March. OpenAI hopes to lock in commitments before Anthropic files its S-1 and lists in mid-November, so as to avoid a direct comparison. Subsequent reports said existing investors such as SoftBank and Abu Dhabi's MGX are i

    Matched fieldsTitle

  5. Story2 reports · 1 facts

    OpenAI launches locked chats feature for ChatGPT

    OpenAI launches a locked chats feature for ChatGPT. According to the official description, this feature moves conversations out of regular history and search and into a protected space; on web and desktop it is unlocked with a PIN, and on supported mobile devices it can be unlocked with a PIN, Face ID, Touch ID, or device unlock; new messages in locked conversations do not update the memory used by regular conversations. The feature is rolling out starting October 21, 2026, to the Free, Go, Plus, Pro, Business, Enterprise, and Edu plans. Follow-up reports add that after users set a 4-digit PIN, they can hide designated conversations from the history list, pinned section, and ordinary search results, tucking them into a "Locked chats" section in the sidebar, covering web, iOS, Android, and the new macOS and Windows desktop apps; locking does not provide end-to-end encryption, nor does it change data retention and model improvement settings, and locked chats may still draw on memory already saved in regular chats; forgetting the PIN itself does not delete chats, but choosing to reset the PIN and confirming will permanently delete all locked chats in the account, memories saved only in locked chats, and files protected only by the old PIN, with no way to recover them.

    OpenAI launches a locked chats feature for ChatGPT. According to the official description, this feature moves conversations out of regular history and search and into a protected space; on web and desktop it is unlocked with a PIN, and on supported mobile devices it can be unlocked with a PIN, Face ID, Touch ID, or device unlock; new messages in locked conversations do not update the memory used by regular conversations. The feature is rolling out starting October 21, 2026, to the Free, Go, Plus

    Matched fieldsTitle

  6. FactRelated story

    OpenAI acquires Orchestra Bio

    OpenAI announced the acquisition of Orchestra Bio. Orchestra Bio is a platform that helps biopharma teams coordinate the complex processes of drug development. According to a Testing Catalog report on October 21, 2026, the two sides will continue development based on OpenAI's Rosalind model and tools for life sciences research, in order to simplify these processes and bring new therapies to patients faster. There are currently no further developments confirmed by factual evidence.

    Matched fieldsTitle

    View story:OpenAI acquires Orchestra Bio

  7. FactRelated story

    Altman tells OpenAI employees they must choose a safety endgame within one year

    According to The Information, Sam Altman told OpenAI employees that the company must decide within the next year which of three safety endgame paths to pursue. The report says the path he favors is to establish an international agency modeled on the International Atomic Energy Agency; this idea can be traced back to a proposal he put forward together with Greg Brockman and Ilya Sutskever in May 2023, under which the agency could inspect systems, require audits, and track compute and energy use. No subsequent developments have been disclosed.

    Matched fieldsTitle

    View story:Altman tells OpenAI employees they must choose a safety endgame path within a year

Saturday

  1. FactRelated story

    OpenAI acquires biotech AI startup Orchestra Bio

    On October 21, 2026, OpenAI announced the acquisition of biotech AI startup Orchestra Bio. According to OpenAI, the platform helps biopharma teams coordinate complex drug development processes, and OpenAI said it will continue building on its life science research models and tools Rosalind to streamline these operational processes and bring new therapies to patients faster. On the same day, OpenAI co-founder Greg Brockman commented on the acquisition, saying that accelerating drug development is an extremely exciting and promising emerging application direction for OpenAI models. The transaction amount has not been disclosed, and there is no further factual disclosure on the specific integration arrangements and business progress after the acquisition.

    Matched fieldsTitle

    View story:OpenAI acquires biotech AI startup Orchestra Bio

Sunday

  2. FactRelated story

    OpenAI launches locked chat feature for ChatGPT

    OpenAI launches a locked chats feature for ChatGPT. According to the official description, this feature moves conversations out of regular history and search and into a protected space; on web and desktop it is unlocked with a PIN, and on supported mobile devices it can be unlocked with a PIN, Face ID, Touch ID, or device unlock; new messages in locked conversations do not update the memory used by regular conversations. The feature is rolling out starting October 21, 2026, to the Free, Go, Plus, Pro, Business, Enterprise, and Edu plans. Follow-up reports add that after users set a 4-digit PIN, they can hide designated conversations from the history list, pinned section, and ordinary search results, tucking them into a "Locked chats" section in the sidebar, covering web, iOS, Android, and the new macOS and Windows desktop apps; locking does not provide end-to-end encryption, nor does it change data retention and model improvement settings, and locked chats may still draw on memory already saved in regular chats; forgetting the PIN itself does not delete chats, but choosing to reset the PIN and confirming will permanently delete all locked chats in the account, memories saved only in locked chats, and files protected only by the old PIN, with no way to recover them.

    Matched fieldsTitle

    View story:OpenAI launches locked chats feature for ChatGPT

  3. Story1 reports · 1 facts

    OpenAI acquires Orchestra Bio

    OpenAI announced the acquisition of Orchestra Bio. Orchestra Bio is a platform that helps biopharma teams coordinate the complex processes of drug development. According to a Testing Catalog report on October 21, 2026, the two sides will continue development based on OpenAI's Rosalind model and tools for life sciences research, in order to simplify these processes and bring new therapies to patients faster. There are currently no further developments confirmed by factual evidence.

    Matched fieldsTitle

  4. Story1 reports · 1 facts

    Altman tells OpenAI employees they must choose a safety endgame path within a year

    According to The Information, Sam Altman told OpenAI employees that the company must decide within the next year which of three safety endgame paths to pursue. The report says the path he favors is to establish an international agency modeled on the International Atomic Energy Agency; this idea can be traced back to a proposal he put forward together with Greg Brockman and Ilya Sutskever in May 2023, under which the agency could inspect systems, require audits, and track compute and energy use. No subsequent developments have been disclosed.

    According to The Information, Sam Altman told OpenAI employees that the company must decide within the next year which of three safety endgame paths to pursue. The report says the path he favors is to establish an international agency modeled on the International Atomic Energy Agency; this idea can be traced back to a proposal he put forward together with Greg Brockman and Ilya Sutskever in May 2023, under which the agency could inspect systems, require audits, and track compute and energy use.

    Matched fieldsTitle

  5. Story1 reports · 1 facts

    Mark Chen welcomes Orchestra Bio to OpenAI

    On October 21, 2026, OpenAI research lead Mark Chen publicly welcomed Orchestra Bio to OpenAI. According to the same report, OpenAI acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex processes of drug development. Mark Chen said the two sides will use Rosalind, an AI model and toolset for life sciences research, to simplify these processes and bring new therapies to patients faster. Currently, this news has only this one source, and there are no subsequent factual developments.

    On October 21, 2026, OpenAI research lead Mark Chen publicly welcomed Orchestra Bio to OpenAI. According to the same report, OpenAI acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex processes of drug development. Mark Chen said the two sides will use Rosalind, an AI model and toolset for life sciences research, to simplify these processes and bring new therapies to patients faster. Currently, this news has only this one source, and there are no subsequent factu

    Matched fieldsTitle

  6. FactRelated story

    Mark Chen welcomes Orchestra Bio to OpenAI

    On October 21, 2026, OpenAI research lead Mark Chen publicly welcomed Orchestra Bio to OpenAI. According to the same report, OpenAI acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex processes of drug development. Mark Chen said the two sides will use Rosalind, an AI model and toolset for life sciences research, to simplify these processes and bring new therapies to patients faster. Currently, this news has only this one source, and there are no subsequent factual developments.

    Matched fieldsTitle

    View story:Mark Chen welcomes Orchestra Bio to OpenAI

Sunday

Tuesday

  1. FactRelated story

    OpenAI accelerates push for roughly $30 billion in financing

    OpenAI is accelerating its push for about $30 billion in financing. According to Reuters, OpenAI is aiming to complete this funding round at a valuation of more than $1.4 trillion before Anthropic goes public, a valuation at least 64% higher than the $852 billion it reached in March. OpenAI hopes to lock in commitments before Anthropic files its S-1 and lists in mid-November, so as to avoid a direct comparison. Subsequent reports said existing investors such as SoftBank and Abu Dhabi's MGX are in talks to participate; OpenAI told investors that growth accelerated after the release of GPT-6 Astra, with annualized revenue already reaching $50 billion and expected to rise to $70 billion by the end of the year. The financing is still in progress.

    Matched fieldsTitle

    View story:OpenAI accelerates push for about $30 billion in financing